Vogenx, Inc.
VOGX evidence brief
What we can confirm
- Market Cap:
- $475.4M
What it means
What to watch
Prepared research question
What matters most for VOGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VOGX
Vogenx, Inc. (VOGX) is a pre-revenue biopharmaceutical company focused on developing SGLT1 inhibitor mizagliflozin for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's syndrome, and VGX-2857 for weight maintenance, with very limited cash and a negative shareholders' equity.
Key risk: Cash runway risk
Market Cap
$475.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 clinical trials for Vogenx, Inc..
Vogenx, Inc. (VOGX) is a pre-revenue biopharmaceutical company focused on developing SGLT1 inhibitor mizagliflozin for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's syndrome, and VGX-2857 for weight maintenance, with very limited cash and a negative shareholders' equity.
- No products approved for commercial sale and no revenue from product sales as of 2026-09-17 [sec_mda].
- Cash and equivalents of $0.2M as of 2026-06-30 [sec].
- Net loss of $0.4M and negative shareholders' equity of $1.8M as of 2026-06-30 [sec].
- Accumulated deficit of approximately $11.7 million as of June 30, 2026 [sec_mda].
- Lead candidate mizagliflozin is in Phase 2 trials for post-bariatric hypoglycemia, with a Phase 2b study started October 1, 2026 [catalyst].
What works
- The company is advancing a pipeline of novel therapeutic product candidates with established endpoints for regulatory approval and large potential market opportunities [sec_mda].
- Mizagliflozin is a selective SGLT1 inhibitor targeting disorders related to glucose absorption and postprandial dysregulation, with Phase 2 clinical data being generated [sec_mda].
- The company has a stated mission and strategy focused on endocrine and metabolic disorders with significant unmet medical needs [sec_mda].
What to weigh
- The company has no approved products and has never generated revenue from product sales [sec_mda].
- Cash and equivalents are extremely low at $0.2M as of 2026-06-30, and shareholders' equity is negative at -$1.8M [sec].
- Accumulated deficit has grown to $11.7 million as of June 30, 2026, and expenses are expected to increase substantially [sec_mda].
- The company warns it may need to seek additional capital and that raising capital could dilute stockholders [sec_mda].
From the filings
Quoted directly from source documents.
No revenue from product sales
“We have no products approved for commercial sale and have not generated any revenue from product sales.”
SEC MD&A · September 17, 2026
Accumulated deficit as of June 30, 2026
“We had an accumulated deficit of approximately $11.7 million and $10.8 million as of June 30, 2026 and December 31, 2025, respectively.”
SEC MD&A · September 17, 2026
Cash and equivalents as of March 31, 2026
“As of March 31, 2026, we had cash and cash equivalents of $251 thousand.”
SEC MD&A · August 10, 2026
Phase 2b study start for mizagliflozin
“Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants With Post-Bariatric Hypoglycemia to Determine the Effect of Mizagliflozin on Hypoglycemia”
Catalysts · October 1, 2026
Catalyst timeline
- 2023-06-23 · Phase 2 start for mizagliflozin in post-bariatric hypoglycemia (initial study) — A Phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study began to evaluate mizagliflozin's effect on adverse events and postprandial glucose excursions.
- 2026-10-01 · Phase 2b start for mizagliflozin in post-bariatric hypoglycemia (EMERGE study) — A Phase 2b randomized, placebo-controlled, double-blind, repeat dose parallel study began to determine the effect of mizagliflozin on hypoglycemia in participants with post-bariatric hypoglycemia.
Risks & what to watch (3)›
Key risks
- Cash runway risk — Cash of only $0.2M as of 2026-06-30; company may need to raise capital soon, risking dilution [sec].
- No revenue, growing losses — No product sales; net loss of $0.4M and accumulated deficit of $11.7M as of 2026-06-30 [sec][sec_mda].
- Clinical development risk — Lead candidate mizagliflozin is still in Phase 2; regulatory approval is uncertain and years away [sec_mda].
What to watch
- Progress of the Phase 2b EMERGE study for mizagliflozin in post-bariatric hypoglycemia, which started October 1, 2026 [catalyst].
- Any new financing or capital raise, given the very low cash position as of 2026-06-30 [sec].
- Initiation of Phase 2 proof-of-concept trial for mizagliflozin in gastroparesis, for which $20.4 million is allocated [sec_mda].
- Updates on VGX-2857 development for weight maintenance [sec_mda].
Sources: Catalysts · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Vogenx, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vogenx, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Vogenx, Inc.?
Vogenx, Inc. (VOGX) is a pre-revenue biopharmaceutical company focused on developing SGLT1 inhibitor mizagliflozin for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing's syndrome, and VGX-2857 for weight maintenance, with very limited cash and a negative shareholders' equity.
Who is the CEO of Vogenx, Inc.?
Mr. James Green is the chief executive officer of Vogenx, Inc. (VOGX).
Where is Vogenx, Inc. headquartered?
Vogenx, Inc. (VOGX) is headquartered in Raleigh, NC, United States.
What therapeutic areas does Vogenx, Inc. focus on?
Vogenx, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.